TD Cowen analyst Phil Nadeau has maintained their bullish stance on CBIO stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Phil Nadeau has given his Buy rating due to a combination of factors that highlight Crescent Biopharma’s promising pipeline and strategic progress. The company is advancing its programs with an IND submission for CR-001 expected in the fourth quarter and CR-002 anticipated by mid-2026. These developments are crucial as they set the stage for potential value inflection points, particularly with the expected release of proof-of-concept data for CR-001 in the second half of 2026.
Furthermore, the preclinical data for CR-001, a PD-1 x VEGF bispecific antibody, validates its design and structure, showing potent anti-tumor activity and favorable safety profiles. The enthusiasm from investigators and key opinion leaders for participating in the clinical development of CR-001 underscores the high conviction in its potential as a standard of care. Additionally, the positive results from the HARMONi-6 trial with a similar antibody further support the potential success of Crescent’s lead asset, contributing to the Buy rating.
According to TipRanks, Nadeau is a 4-star analyst with an average return of 5.9% and a 46.38% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Kura Oncology, Dynavax, and Apellis Pharmaceuticals.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $22.00 price target.